©The Author(s) 2025.
World J Psychiatry. Oct 19, 2025; 15(10): 110968
Published online Oct 19, 2025. doi: 10.5498/wjp.v15.i10.110968
Published online Oct 19, 2025. doi: 10.5498/wjp.v15.i10.110968
Table 2 Exposure and dose modification (full analysis set), mean ± SD
| Lurasidone (40 mg/day), n = 99 | Lurasidone (80 mg/day), n = 98 | Overall, n = 197 | |
| Exposure days on drug (day) | 38.6 ± 9.16 | 32.7 ± 14.55 | 35.7 ± 12.46 |
| Total exposure level (mg) | 2436.4 ± 803.89 | 2492.0 ± 1147.47 | 2464.1 ± 987.69 |
| Average daily dose (mg/day) | 62.45 ± 13.62 | 76.72 ± 8.58 | 69.55 ± 13.43 |
| Dose modification during the second week (%) | 60.6 | 8.2 | 34.5 |
- Citation: Liu Q, Qian MC, Liu ZF, Dong F, Liu DT, Li ML, Ning YP, Wang XP, Liu TB, Wu Q, Li T, Yu X. Safety and efficacy of different initial doses of lurasidone in the schizophrenia treatment: A multi-center, randomized, open-label study. World J Psychiatry 2025; 15(10): 110968
- URL: https://www.wjgnet.com/2220-3206/full/v15/i10/110968.htm
- DOI: https://dx.doi.org/10.5498/wjp.v15.i10.110968